Stem Cell Therapy for Autism Restricted to Approved Clinical Trials: Centre

Gist The Union Health Ministry has directed States and Union Territories to restrict the use of stem cell therapy for Autism Spectrum Disorder ASD exclusively to duly approved clinical trials. The advisory strictly prohibits clinical establishments from offering stem cell interventions for autism as standard, routine, or commercial care. For an aspirant, this development is crucial as it links judicial oversight with public health regulation, highlighting the mechanisms used by the state to curb the commercial exploitation of unproven medical technologies under the guise of advanced treatment. Background Stem cell therapy involves using undifferentiated cells to regenerate or repair diseased tissues, but its scientifically proven applications are currently limited to very specific conditions, primarily blood disorders like leukemia. The sector is regulated by the National Guidelines for Stem Cell Research, 2017 , jointly formulated by the Indian Council of Medical Research ICMR and the Department of Biotechnology , which mandate that unproven therapies can only be administered within strictly monitored clinical trials. Before this enforcement, a regulatory gray area allowed private clinics to market expensive and scientifically unvalidated stem cell…